anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
High rates of asthma morbidity and mortality among inner-city African American and Hispanic adolescents demand urgent intervention. To address this disparity, the investigators have designed a culturally sensitive intervention aimed at improving adherence to daily controller medications for asthma, and ultimately reduce asthma exacerbation risk, that fits easily into adolescents' chaotic lifestyles.

The proposed study is a behavioral randomized controlled trial that tests if a coping peer intervention can increase adherence to asthma controller medications among urban African American and Hispanic adolescents 11 to 16 years of age. To ensure the project's success, the principal investigator has assembled a multi-disciplinary team of researchers, including behavioral and social science experts. The Specific Aims propose to: (1) evaluate the impact of a 10-week coping peer support intervention on adherence and knowledge, compared to an attention control; (2) evaluate the ability of a 10-week coping peer support intervention to achieve sustained post-treatment improvements in adherence and knowledge, compared to an attention control; and (3) to develop estimates needed for the design of a subsequent R01 behavioral controlled trial testing the efficacy of this intervention to decrease risk of asthma exacerbations. The study's primary outcome is adherence to daily asthma controller medications, measured using an objective electronic monitor. Study participants will be randomized to receive equal asthma supervision and music tracks plus either: (1) group support, coping peer group problem solving, and peer delivered asthma messages (intervention group); or (2) study team developed and recorded asthma health messages (attention control group) between music tracks, on a portable MP3 player. The group support and coping peer group problem solving consists of: putting subjects together in a small group to discuss barriers to adherence and ways to overcome these barriers; then having group members record messages to each other about overcoming barriers that will be played on their MP3 player, between music tracks, during the course of their daily routines. This effectively brings the coping peer support from the group into the course of the adolescents' day-to-day lives. The investigators hypothesize that it is the ability of the MP3 player to facilitate ongoing peer support that will be the basis for improved adherence. The long term goal is to apply the data from this research to submit an R01 grant application to conduct a behavioral randomized trial evaluating the effectiveness of this coping peer intervention to improve adherence, and ultimately reduce asthma exacerbations, in urban African American and Hispanic adolescents with asthma.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, specifically to combustiology and surgery. The technique involves preliminary abrasion of a wound and application of fibroblasts on the wound surface. The fibroblasts are distributed in a gel mixture. Said gel mixture contains a serum-free nutrient medium and methylcellulose in amount 1.0 - 3.0 wt %. ^ EFFECT: method prolongs viability of the cells applied on the wound, prevents occurrence of allergic reaction. ^ 5 cl, 3 ex, 1 tbl, 5 dwg
FIELD: biotechnology, microbiology. SUBSTANCE: invention proposes new strain of Listeria monocytogenes VGNKI N UCHI-52-DEP. Strain is avirulent, selected by cultural-morphological, biological and serological characters and stored in Museum VGNKI veterinary preparations. Strain is used for vaccine preparing against listerellosis in agriculture animals. EFFECT: enhanced effectiveness of vaccine, new strain indicated above. 2 tbl
Patients receive ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
Patients with unresectable intrahepatic CCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
Patients will be randomized to treatment at their first gout flare in the study. The first treatment period will be followed by an extension period during which the patients will receive the same treatment for any subsequent flares within 52 weeks of randomization of last patient in the study. The extension period for the individual patient in the study will be maximum two years (104 weeks). Each new flare treated will initiate a new series of study visits and assessments according to specified schedule of events. Only if a patient experience a new flare after Day 15 of the latest flare they can start a new treatment period. The comparison of primary interest is between anakinra (100 mg and 200 mg combined) and 40 mg triamcinolone, and as a secondary objective the 2 different doses of anakinra will be evaluated as well as assessment for subsequent flares.
NEW MATERIAL:The compound of formula I [the group of formula II is (substituted)alicyclic amino; R<1> is lower alkyl or aralkyl; R<2> is H or lower alkyl]. EXAMPLE:3-Cyano-2-methylthio-1-( 4-phenyl-piperidino-carbonyl )-4H-quinolizin-4- one. USE:Medicine. It has an activity to suppress the formation of antibody of immunoglobulin E (IgE) and is useful as a remedy for diseases caused by IgE, e.g. bronchial asthma, rhinitis, dermatitis, anaphylaxis, etc. PREPARATION:The compound of formula I can be produced by reacting 2- pyridylacetic acid with an amine derivative of formula III and reacting the resultant 2-pyridylacetamide derivative of formula IV (including novel compounds) with equimolar amount of a compound of formula V in an inert solvent or in the absence of solvent by heating at 100-120 deg.C for 2-10hr. The compound of formula V can be produced by the reaction of methyl cyanoacetate, CS2 and a compound of formula R<2>-X (X is acid residue).
A sustained release coated pellet or tablet containing a pharmaceutically active ingredient soluble in the fluids of the gastro-intestinal tract is coated with a layer comprising one or more areas impermeable by said fluids and pharmaceutically active ingredient and one or more other areas provided by a dialysing membrane permeable by said fluids and pharmaceutically active ingredient.  The dialysing membrane may be formed from a natural or synthetic film-forming material, e.g. cellulose acetate, collodion, acrylic, or phenolic polymers, but preferably from an ion exchange resin, e.g. sulphonated polystyrene, resorcinol-type resins, carboxylic acid resins, phenolformaldehyde polyamine resins, polystyrene polyamine resins, or polystyrene quaternary amine resins. A pH buffering substance capable of maintaining the pH at the surface of the tablet at or below about 7.3 may be incorporated in the tablet.  In one form, the medicament may be enveloped in a porous membrane, the outer surface of which is coated in selected areas with a layer of impermeable material.  In another form, the medicament may be enclosed in an impermeable plastics shell having a number of passageways passing therethrough which are sealed by dialysing membranes.  In a modification, the medicament may be sealed by the dialysing membranes in passageways passing through an impermeable plastics body, e.g. of polymethyl methacrylate or polytetrafluoroethylene.  In yet another arrangement, the active ingredient is coated with a dialysing membrane and encased in a rigid plastics jacket having a number of apertures therein.  The pharmaceutically active ingredient may be in liquid or powder form. Specified active ingredients comprise antibiotics, e.g. oxytetracycline hydrochloride, sedatives, and vermifuges.
Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
Participants in the control arm will receive standard-of-care counseling on partner notification following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The same counseling will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
PURPOSE: The efficacy of factor Xa inhibitors in patients with atrial fibrillation (AF) and rheumatic heart disease (RHD) is unknown.
METHODS/RESULTS: The objective of this article was to conduct a comprehensive evaluation of the INVICTUS trial, an open-label randomized controlled study that compared vitamin K antagonists (VKA) to rivaroxaban in patients with AF and RHD while also considering the existing evidence from literature in this particular area of research.
CONCLUSION: The findings of the INVICTUS trial indicated that rivaroxaban was found to be inferior in efficacy to VKA. However, it is important to note that the primary outcome of the trial was driven by sudden death and death caused by mechanical pump failure. As a result, it is necessary to approach the data from this study with caution, and it would be inappropriate to draw parallel conclusions for other causes of valvular AF. Particularly, the perplexing issue of how rivaroxaban could have contributed to both pump failure and sudden cardiac death requires further explanation. Additional data regarding changes in heart failure medication and ventricular function would be essential for proper interpretation.
<P>PROBLEM TO BE SOLVED: To provide a nucleic acid external preparation for skin comprising a nucleic acid oligonucleotide in relation to a pharmaceutical preparation comprising the nucleic acid.  <P>SOLUTION: This nucleic acid external preparation for skin having high skin permeability is provided by formulating the nucleic acid which is a polymer into the preparation by using sodium alginate or a mixture of soybean phospholipids with vaseline. Since the nucleic acid external preparation for skin has the high skin permeability, the nucleic acid which is an active ingredient can efficiently be delivered to an affected part. The dose of the nucleic acid to be used may be low and even safety and economical efficiency are excellent. Since the mechanism of action is different from that of a low-molecular compound which is an active ingredient of the currently used skin anti-inflammatory agent, effects can be expected even for a case in which a low-molecular medicine is not effective.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualisation will be established by compliance guided end-expiratory and peak pressure setting during double lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
Vocal fold atrophy, scar, sulcus vocalis, glottal insufficiency with resulting dysphonia is a condition affecting millions of aging Americans, up to 35% of those 65 or older. Currently used treatment methods include voice therapy, injections of inert fillers, and laryngeal framework surgery. These modalities are imperfect with voice therapy requiring considerable time commitment, filler injections generally temporary in benefit, and surgery with increased risks. The investigators intend to conduct a single-arm study to assess the safety and efficacy of autologous platelet-rich plasma (PRP) injection for vocal fold atrophy, sulcus vocalis and scar. PRP is a substance purified from the patient's own blood that consists of platelets, growth factors, and other regenerative molecules that have been shown to promote rejuvenation in a variety of tissue types. Patients with vocal fold atrophy, sulcus vocalis, and scar identified in the USC Voice Center will be offered participation in a study to receive serial PRP injections in one vocal fold. Outcome measures evaluated pre- and post-injection and over follow-up visits will include various patient reported quality of life indices, objective clinical assessments of voice, and laryngeal videostroboscopy examinations. The investigators hypothesize that serial PRP injections will significantly improve vocal fold mucosal volume, morphology, and dysphonia in these patients with no adverse side effects.
Half (53) of the participants will be randomly allocated to the Transition Coach Intervention arm of the study. Individuals in the Transition Coach Intervention group will receive the current standard of care (receiving the Youth Transition Roadmap) and meet with the transition coach six times and with a clinical psychologist two times over the course of six months. The meetings between the participant and TC/psychologist will occur over the phone or using the Ontario Telemedicine Network or EPIC.
Stroke is the rapidly developing loss of brain functions due to disturbance in the blood supply to the brain. It is the leading cause of adult disability in the United States and Europe and currently the second leading cause of death, ranking after heart disease and before cancer, accounting for 10% of deaths worldwide . About 80-90% of strokes are caused by ischemia, and the remainder by hemorrhage . Arterioarterial micro thromboembolism is an important etiological factor in the pathogenesis of ischemic stroke. Platelet activation in cerebrovascular disease is associated with recurrent stroke and death, while inhibition of platelet function by antiplatelet drugs including aspirin lowers the risk of ischemic stroke. Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events. Yet, some patients experience recurrent ischemic events despite optimal antiplatelet therapy. This has raised the possibility that these patients may be resistant to aspirin and generated much interest in identification of such patients with laboratory tests of platelet function. Although many studies have demonstrated aspirin resistance in cardiovascular disorders including coronary artery disease, metabolic syndrome , and diabetes by certain tests of aspirin resistance, there are still concerns that these tests have not correlated closely with subsequent recurrent events, and have not reliably identified non-responders to antiplatelet therapy . In addition to the absence of any standardized approach to the diagnosis, there is currently no proven effective treatment for aspirin resistance. Although aspirin resistance has been demonstrated as a possible risk factor for recurrent cardiovascular ischemic events, there is a lack of data correlating aspirin resistance and risk of cerebrovascular ischemic events
Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
Various methods for propagating and rescuing multiple serotypes of replication-defective adenovirus in a single adenoviral E1-complementing cell line are disclosed. Typically, replication-defective adenovirus vectors propagate only in cell lines which express E1 proteins of the same serotype or subgroup as the vector. The disclosed methods offer the ability to propagate vectors derived from multiple adenoviral serotypes in a single production cell line which expresses E1 proteins from a single serotype. Propagation in this manner is accomplished by providing all or a portion of an E4 region in cis within the genome of the replication-defective adenovirus. The added E4 region or portion thereof is cloned from a virus of the same or highly similar serotype as that of the E1 gene product(s) of the complementing cell line. Interaction between the expressed E1 of the cell line and the heterologous E4 of the replication-defective adenoviral vectors enables their propagation and rescue.  The invention bypasses a need in the art to customize specific cell lines to the serotype or subgroup of the adenoviral vector being propagated and enables one to easily and rapidly develop alternative adenoviral serotypes as gene delivery vectors for use as vaccines or as a critical component in gene therapy.
Progressive Muscle Relaxation was recorded for uniformity of delivery, and was 22 minutes in length. It was played on a speaker at equal volume to ensure uniformity.
Chronic pelvic pain associated with endometriosis is poorly understood. This study is an effort to better understand pelvic pain and identify novel medical approaches for treating it. Endometriosis is a very common disease of women in their reproductive years, in which endometrial tissue grows outside the uterus. In a recent epidemiologic study, we have shown strong associations among endometriosis, fibromyalgia, and autoimmune disorders. Currently, it is believed that endometriosis causes chronic pelvic pain. Yet, some women with endometriosis do not have any pain and others have pain in areas unrelated to endometriosis disease location. The standard approaches to treating endometriosis pain have been to medically alter hormone levels to prevent endometriosis tissue growth or to surgically remove endometriosis lesions. Pelvic pain is only temporarily treated by either approach, which suggests that the current classification of pain, based on disease and treatment with hormones or surgery is not adequate. The feeling of pain involves many complex processes. Generally, women suffer more frequently from chronic, long-term, painful conditions than men. This suggests that women process pain differently because of differences in sex hormone levels and genes expressed in a sexually dimorphic fashion, as well as in central nervous and immune system function differences. We will examine the relations among sex hormones, pain processing, immune system substances and pain related genes. We will also examine changes in levels of hormonal and immune substances in the blood, endometriosis lesions and normal endometrial tissue. Myofascial pain has been noted in women with endometriosis and chronic pelvic pain. We will study how the nerve, muscle and skeletal systems are involved in pelvic pain by performing an in depth pain assessment. Finally, stress plays an important role generating and perpetuating chronic pain. We will examine how the hormones related to the stress response may be altered in pelvic pain.
Heart rate variability (HRV) is an important indicator of an organism's ability to adapt and regulate autonomic cardiac function. High heart rate variability is an indicator of good adaptability to physical and mental demands, while decreased HRV is associated with increased vulnerability to psychological and physical stressors. Previous studies have shown that the central autonomic network, composed of several regions of the brain such as the amygdala and prefrontal cortex, play an important role in regulating heart rate variability. However, the exact neural correlates and underlying neural mechanisms involved in autonomic cardiac control are still a subject of investigation. Furthermore, the dynamic connectivity between heart rate variability and the central autonomic network under changing physiological circumstances remains largely unexplored. This study seeks to investigate which regions of the brain are especially relevant in the regulation of cardiac control and how the interplay between HRV and those regions change during different physiological states (stress versus relaxation). In order to achieve this, we will use functional magnetic resonance imaging (fMRI) during an experimental task consisting of deep breathing and a psychosocial stress task (Montreal Imaging Stress Task). This paradigm will allow assessing the dynamic interplay between the heart and the brain. 30 healthy participants will be recruited, in addition to fMRI scanning participants will perform a psychometric test battery. A better understanding of these psychobiological mechanisms is a fundamental requirement for a better understanding of the autonomic regulation of HRV and the development of improved treatment strategies for disorders characterized by an impaired autonomic system and reduced HRV.
Described herein are compositions, kits, and methods for the effective delivery of cells to a subject. The cells may be cells of a particular cell type, such as basal cells, ciliated cells, or secretory cells. In some cases, the cells may be lung cells of a particular cell type. Also described herein are pharmaceutical compositions comprising therapeutic or prophylactic agents assembled to lipid compositions. The lipid composition may comprise an ionizable cationic lipid, a phospholipid, and a selective organ-targeting lipid. Further described herein are highly potent dosage forms of therapeutic or prophylactic agents formulated with lipid compositions.
Lipid nanoparticles (LNPs) have emerged as a promising delivery vehicle for realizing the therapeutic potential of RNA. Developing effective extrahepatic-targeting LNP formulations has been elusive, however, particularly when targeting the central nervous system (CNS). This work demonstrates the ability of AiLNP, METiS' proprietary AI-driven organ-targeted LNP discovery engine, to rapidly (<2 months) create proprietary LNPs specifically optimized for CNS delivery. AiLNP-designed LNPs loaded with siRNA achieved >80%knockdown of HTT mRNA in the whole brain of adult mice after a single intrathecal dose of 0.75 mg/kg siRNA, while naked siRNA was unable to achieve knockdown at any dose. Tissue microscopy found that the optimized LNPs uniformly delivered siRNA to deep brain regions in the cortex, hippocampus, and cerebellum. The LNPs showed clear signs of safety, with no hematologic toxicity, systemic bleeding, or body weight changes. Beyond siRNA, AiLNP has also been applied to optimize LNPs for CNS delivery of mRNA and ASOs. These results highlight the potential of AiLNP to significantly improve the design of LNPs that can successfully deliver payloads to the CNS.